-
Rocket Pharmaceuticals stockholders elect directors, ratify auditor, approve say-on-pay and stock option exchange
Seven director nominees elected; David P. Southwell received 43.2M for, 20.1M withheld (lowest support).
-
Rocket Pharma Q1 net loss $47.6M; KRESLADI gets FDA accelerated approval; PRV sold for $180M
Net loss of $47.6M ($0.42/sh) narrowed from $61.3M ($0.56/sh) YoY.
-
Rocket Pharmaceuticals sells Rare Pediatric Disease PRV for $180M, extending cash runway to Q2 2028
Enters definitive agreement to sell PRV for $180M in cash; closing subject to HSR antitrust waiting period.
-
FDA approves Rocket's gene therapy KRESLADI for severe LAD-I; Rare Pediatric PRV granted
KRESLADI (marnetegragene autotemcel) approved for pediatric severe LAD-I with no HLA-matched sibling donor.
-
Rocket Pharma enters $100M ATM equity facility with Cantor Fitzgerald
Agreement with Cantor Fitzgerald to sell up to $100M of common stock via at-the-market offerings.
-
Rocket Pharma FY2025 net loss $223.1M; cash $188.9M; KRESLADI PDUFA March 28, 2026
Net loss $223.1M ($2.01/shr) vs $258.7M ($2.73/shr) in FY2024; R&D spend down 17% to $142.0M.
-
Rocket Pharma Q3 net loss $50.3M; KRESLADI PDUFA March 2026; Danon trial to resume 1H 2026
Q3 net loss $50.3M ($0.45/share), down from $66.7M ($0.71) YoY; R&D expenses $34.1M vs $42.3M.
-
Rocket Pharma: FDA accepts BLA resubmission for KRESLADI gene therapy; PDUFA March 28, 2026
FDA accepted BLA resubmission for KRESLADI (marne-cel) for severe LAD-I; PDUFA target date March 28, 2026.
-
Rocket Pharma withdraws BLA for RP-L102 (Fanconi anemia gene therapy) as part of corporate prioritization
Voluntarily withdrew BLA for RP-L102 (mozafancogene autotemcel) from FDA on October 3, 2025.
-
Director Pedro Granadillo resigns from Rocket Pharmaceuticals board effective Sept 30, 2025
Pedro Granadillo resigned from Board on Sept 29, 2025, effective Sept 30, 2025.
-
Rocket Pharmaceuticals appoints Dr. Peter Fong to Board; Dr. Gotham Makker resigns
Dr. Gotham Makker resigned from the Board effective Sept 24, 2025; no disagreement on operations, policies, or practices.
-
Rocket Pharma finalizes Dr. Patel separation; consulting through Dec 2026 with $582K retainer
Dr. Kinnari Patel receives $482,040 lump-sum severance (10 months salary) and $30,045 healthcare allowance.
-
Rocket Pharma CFO resigns; General Counsel named interim CFO
Aaron Ondrey resigned as CFO effective September 5, 2025 to pursue other opportunities.
-
Rocket Pharmaceuticals: FDA lifts clinical hold on Phase 2 trial of RP-A501 for Danon disease
FDA lifted clinical hold in under 3 months; trial resumes with recalibrated dose 3.8x10^13 GC/kg for 3 patients with 4-week intervals.
-
Rocket Pharmaceuticals: President Patel to depart, 30% workforce cut, Q2 net loss $68.9M
Dr. Kinnari Patel to leave as President and Head of R&D effective Dec 31, 2025; steps down Aug 8.
-
Rocket Pharma restructures, cuts headcount 30%, delays FA/PKD programs; cash runway to Q2 2027
Headcount reduction of ~30% and 12-month cash burn reduction of ~25% as part of corporate reorganization.
-
Rocket Pharmaceuticals cuts workforce 30%, extends cash runway into Q2 2027
Reduction in workforce of ~30%; expected to cut 12-month operating expenses by ~25%.
-
FDA grants RMAT designation to Rocket Pharma's RP-A601 gene therapy for PKP2-ACM
FDA granted RMAT designation for RP-A601 (AAV-based gene therapy) for PKP2-arrhythmogenic cardiomyopathy.
-
Rocket Pharmaceuticals appoints Christopher Stevens as COO; Patel shifts to President, Head of R&D
Christopher Stevens, age 45, appointed COO effective July 7, 2025; previously EVP at Spark Therapeutics.
-
Rocket Pharma annual meeting: all director nominees elected, auditor ratified, say-on-pay approved
10 director nominees elected; David P. Southwell received 55.4M for vs 23.8M withheld, still elected on plurality standard.
-
Rocket Pharma announces FDA clinical hold on Phase 2 Danon gene therapy trial after patient death
Patient in Phase 2 trial of RP-A501 experienced SAE (capillary leak syndrome) and later died due to acute systemic infection.
-
Rocket Pharma reports positive Phase 1 data for RP-A601 in PKP2-ACM
RP-A601 well-tolerated; no dose-limiting toxicities in 3 patients with up to 12 months follow-up.
-
Rocket Pharma Q1 net loss $61.3M; cash $318.2M; pipeline on track
Net loss of $61.3M ($0.56/share) vs $62.1M in Q1 2024; R&D expenses down to $35.9M.
-
Director R. Keith Woods not standing for re-election to Rocket board
R. Keith Woods informed board he accepted COO role at another biopharma company; will not stand for re-election at 2025 annual meeting.
-
Rocket Pharma appoints Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer
Annual base salary of $525,000 with a target bonus of 45% of salary.
-
Rocket Pharma FY2024 net loss $258.7M ($2.73/sh); cash $372.3M; RP-A501 Phase 2 ongoing
Net loss $258.7M ($2.73/sh) for FY2024 vs $245.6M ($2.92/sh) in FY2023.
-
Rocket Pharmaceuticals appoints Piratip Pratumsuwan to Board; Yalamanchi resigns
Naveen Yalamanchi resigned from Board effective Jan 25, 2025; no disagreement.
-
Rocket Pharmaceuticals raises ~$182.8M in public offering and private placement
Public offering of 15.18M shares at $12.50/sh, including full exercise of underwriters' option; net proceeds ~$178.1M.
-
Rocket Pharma GM Commercial Affairs Mark White resigns effective Jan 1
Mark White resigns as General Manager, Commercial Affairs, effective January 1, 2025.
-
Rocket Pharma reports positive long-term Phase 1 Danon Disease data; PKD program enrollment delayed to 2025
All evaluable Danon disease patients showed cardiac LAMP2 protein expression at 12 months, sustained up to 60 months, and ≥10% LV mass index reduction sustained up to 54 months.
-
Rocket Pharma Q3 2024 net loss $198.4M; cash $235.7M; pipeline advances
Net loss $198.4M ($2.11/share) for nine months ended Sept 30, 2024, vs $185.9M ($2.30/share) prior year.
-
Rocket Pharmaceuticals appoints Dr. Mikael Dolsten to board
Dr. Mikael Dolsten appointed to board effective September 9, 2024.
-
Rocket Pharma H1 2024 net loss $131.7M; KRESLADI review ongoing, cash into 2026
Net loss of $131.7M ($1.40/sh) for H1 2024 vs $124.0M ($1.55/sh) for H1 2023.
-
Rocket Pharma receives FDA Complete Response Letter for KRESLADI BLA; limited CMC info requested
FDA issued Complete Response Letter for KRESLADI (marne-cel) BLA; requested limited additional CMC information.
-
Rocket Pharma increases authorized shares to 180M after shareholder approval
Authorized common shares increased from 120M to 180M (50% increase); amendment effective June 20, 2024.
-
Rocket Pharma Q1 net loss $62.1M; cash $330.3M; EMA accepted MAA for FA, PDUFA date June 30 for LAD-I
Net loss of $62.1M ($0.66/sh) vs $58.3M ($0.73/sh) in Q1 2023; G&A rose to $22.1M on commercial prep.